EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Metabolic Syndrome Management Through Cannabidiol‐Loaded PLGA Nanoparticles: Development and In Vitro Evaluation

Mazen M El-Hammadi iD, Lucía Martín-Navarro, Esther Berrocoso, Josefa Álvarez-Fuentes, Benedicto Crespo-Facorro, Irene Suárez-Pereira, Javier Vázquez-Bourgon, Lucía Martín-Banderas iD

Journal of Biomedical Materials Research Part A · 2025-05 · 113 (5)

DOI: 10.1002/jbm.a.37916 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 25.04.2025. Verfasst von Mazen M El-Hammadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, Sevilla, Spain. Hauptthemen laut MEDLINE: Nanoparticles, Polylactic Acid-Polyglycolic Acid Copolymer, Metabolic Syndrome, Cannabidiol. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors especially thank the financial support from the Instituto de Investigación Sanitaria Valdecilla (IDIVAL; INNVAL18/30; INT22/00029) and Plan Estatal…, Instituto de Investigación Sanitaria Valdecilla, Plan Estatal 2021-2023, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabidiol (CBD) holds promise for managing metabolic diseases, yet enhancing its oral bioavailability and efficacy remains challenging. To address this, we developed polymeric nanoparticles (NPs), using poly(lactic‐co‐glycolic acid) (PLGA), encapsulating CBD using nanoprecipitation, aiming to create an effective CBD‐nanoformulation for metabolic disorder treatment. These NPs (135–265 nm) demonstrated high encapsulation efficiency (EE% ≈ 100%) and sustained release kinetics. Their therapeutic potential was evaluated in an in vitro metabolic syndrome model employing sodium palmitate‐induced HepG2 cells. Key assessment parameters included cell viability (MTT assay), glucose uptake, lipid accumulation (Oil Red O staining), triglycerides, cholesterol, HDL‐c levels, and gene expression of metabolic regulators. Results showed an IC50 of 9.85 μg/mL for free CBD and 11.26 μg/mL for CBD‐loaded NPs. CBD‐loaded NPs significantly enhanced glucose uptake, reduced lipid content, lowered triglycerides and total cholesterol, and increased HDL‐c levels compared to free CBD. Gene analysis indicated reduced gluconeogenesis via downregulation of PPARγ, FOXO‐1, PEPCK, and G6Pase and enhanced fatty acid oxidation through CPT‐1 upregulation. These findings suggest that CBD‐loaded NPs may serve as a novel therapeutic strategy for the management of metabolic disorders, warranting further in vivo studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerMetabolic SyndromeCannabidiolHumansHep G2 CellsGlucoseCell Survival

Stichwörter der Autor:innen

antipsychoticscannabidioldiabeteslipid metabolismmetabolic disordersnanomedicine

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymerCannabidiolGlucose

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, Sevilla, Spain.
  • Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
  • Neuropsychopharmacology & Psychobiology Research Group, Department of Psychology, University of Cadiz, Cádiz, Spain.
  • Biomedical Research and Innovation Institute of Cádiz (INiBICA) Research Unit, Puerta del Mar University Hospital, University of Cádiz, Cádiz, Spain.
  • Instituto de Biomedicina de Sevilla (IBIS)-Campus Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio, Sevilla, Spain.

ORCID-Profile: Mazen M El-Hammadi, Lucía Martín-Banderas

Förderung

  • The authors especially thank the financial support from the Instituto de Investigación Sanitaria Valdecilla (IDIVAL; INNVAL18/30; INT22/00029) and Plan Estatal…
  • Instituto de Investigación Sanitaria Valdecilla
  • Plan Estatal 2021-2023, Ministerio de Ciencia e Innovación
  • Ministerio de Sanidad, Gobierno de España
  • Ministerio de Ciencia e Innovación
  • Ministerio de Sanidad, Consumo y Bienestar Social

Zitieren

APA

El-Hammadi, M. M., Martín-Navarro, L., Berrocoso, E., Álvarez-Fuentes, J., Crespo-Facorro, B., Suárez-Pereira, I., Vázquez-Bourgon, J., & Martín-Banderas, L. (2025). Enhanced Metabolic Syndrome Management Through Cannabidiol‐Loaded PLGA Nanoparticles: Development and In Vitro Evaluation. Journal of Biomedical Materials Research Part A, 113(5). https://doi.org/10.1002/jbm.a.37916

Vancouver

El-Hammadi MM, Martín-Navarro L, Berrocoso E, Álvarez-Fuentes J, Crespo-Facorro B, Suárez-Pereira I, et al. Enhanced Metabolic Syndrome Management Through Cannabidiol‐Loaded PLGA Nanoparticles: Development and In Vitro Evaluation. Journal of Biomedical Materials Research Part A. 2025;113(5). doi:10.1002/jbm.a.37916

BibTeX
@article{ElHammadi2025,
  author = {El-Hammadi, Mazen M and Martín-Navarro, Lucía and Berrocoso, Esther and Álvarez-Fuentes, Josefa and Crespo-Facorro, Benedicto and Suárez-Pereira, Irene and Vázquez-Bourgon, Javier and Martín-Banderas, Lucía},
  title = {Enhanced Metabolic Syndrome Management Through Cannabidiol‐Loaded PLGA Nanoparticles: Development and In Vitro Evaluation},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2025},
  volume = {113},
  number = {5},
  doi = {10.1002/jbm.a.37916}
}
Kostenlos starten →